JPWO2020163365A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020163365A5 JPWO2020163365A5 JP2021545400A JP2021545400A JPWO2020163365A5 JP WO2020163365 A5 JPWO2020163365 A5 JP WO2020163365A5 JP 2021545400 A JP2021545400 A JP 2021545400A JP 2021545400 A JP2021545400 A JP 2021545400A JP WO2020163365 A5 JPWO2020163365 A5 JP WO2020163365A5
- Authority
- JP
- Japan
- Prior art keywords
- zc3h12a
- socs1
- optionally
- immune effector
- targeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024098698A JP2024111155A (ja) | 2019-02-04 | 2024-06-19 | 免疫療法の改善のための遺伝子標的の組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800999P | 2019-02-04 | 2019-02-04 | |
| US62/800,999 | 2019-02-04 | ||
| US201962818677P | 2019-03-14 | 2019-03-14 | |
| US62/818,677 | 2019-03-14 | ||
| PCT/US2020/016623 WO2020163365A2 (en) | 2019-02-04 | 2020-02-04 | Combination gene targets for improved immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024098698A Division JP2024111155A (ja) | 2019-02-04 | 2024-06-19 | 免疫療法の改善のための遺伝子標的の組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519595A JP2022519595A (ja) | 2022-03-24 |
| JPWO2020163365A5 true JPWO2020163365A5 (enExample) | 2023-02-10 |
Family
ID=71947815
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545400A Pending JP2022519595A (ja) | 2019-02-04 | 2020-02-04 | 免疫療法の改善のための遺伝子標的の組み合わせ |
| JP2024098698A Pending JP2024111155A (ja) | 2019-02-04 | 2024-06-19 | 免疫療法の改善のための遺伝子標的の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024098698A Pending JP2024111155A (ja) | 2019-02-04 | 2024-06-19 | 免疫療法の改善のための遺伝子標的の組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200347386A1 (enExample) |
| EP (1) | EP3920942A4 (enExample) |
| JP (2) | JP2022519595A (enExample) |
| KR (1) | KR20210138587A (enExample) |
| CN (1) | CN113396216A (enExample) |
| AU (1) | AU2020217715A1 (enExample) |
| BR (1) | BR112021015170A2 (enExample) |
| CA (1) | CA3128823A1 (enExample) |
| IL (1) | IL285307A (enExample) |
| MX (1) | MX2021009357A (enExample) |
| SG (1) | SG11202108452WA (enExample) |
| WO (1) | WO2020163365A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019236204B2 (en) | 2018-03-15 | 2026-02-26 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| JP2021518160A (ja) | 2018-03-15 | 2021-08-02 | ケーエスキュー セラピューティクス， インコーポレイテッド | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 |
| GB202013477D0 (en) * | 2020-08-27 | 2020-10-14 | Quell Therapeutics Ltd | Nucleic acid constructs for expressing polypeptides in cells |
| CN116648507A (zh) * | 2020-08-28 | 2023-08-25 | 基因泰克公司 | 宿主细胞蛋白的CRISPR/Cas9多重敲除 |
| US20240060091A1 (en) * | 2020-12-17 | 2024-02-22 | University of Florida Research Foundation, Incorporation | Method for programmable control of rna transcript levels with autoregulated crispr-cas13d |
| AU2022216614B2 (en) | 2021-02-05 | 2026-03-05 | Christiana Care Gene Editing Institute, Inc. | Methods of and compositions for reducing gene expression and/or activity |
| US12553030B2 (en) | 2021-03-09 | 2026-02-17 | Crispr Therapeutics Ag | Genetically engineered T cells with PTPN2 knockout have improved functionality and anti-tumor activity |
| WO2023015213A1 (en) * | 2021-08-03 | 2023-02-09 | Spotlight Therapeutics | Ptpn2 specific guide rnas and uses thereof |
| KR20240099259A (ko) | 2021-10-14 | 2024-06-28 | 아스널 바이오사이언시스, 인크. | 공동 발현된 shrna 및 논리 게이트 시스템을 갖는 면역 세포 |
| US20250352647A1 (en) * | 2021-11-10 | 2025-11-20 | Tsinghua University | Method for enhancing durability of immune cell |
| EP4436967A4 (en) * | 2021-11-23 | 2025-10-22 | Kumquat Biosciences Inc | COMPOUNDS CONTAINING HETEROATOMS AND THEIR USES |
| KR20240130120A (ko) * | 2022-01-05 | 2024-08-28 | 쑤저우 인스티튜트 오브 시스템즈 메디슨 | T 세포 수용체 및 이의 제조 방법과 용도 |
| CN118401651A (zh) * | 2022-01-29 | 2024-07-26 | 苏州沙砾生物科技有限公司 | 一种修饰的肿瘤浸润淋巴细胞及其用途 |
| JP2026507228A (ja) | 2023-03-03 | 2026-02-27 | アーセナル バイオサイエンシズ インコーポレイテッド | Ｐｓｍａ及びｃａ９を標的とするシステム |
| TW202500126A (zh) | 2023-05-24 | 2025-01-01 | 美商金橘生物科技公司 | 雜環化合物及其用途 |
| CN116790667A (zh) * | 2023-07-12 | 2023-09-22 | 中国医科大学 | 巨噬细胞条件性基因敲除小鼠模型的建立及其应用 |
| WO2025054946A1 (zh) * | 2023-09-15 | 2025-03-20 | 毕诺济(上海)生物技术有限公司 | 敲除Roquin-1和/或Regnase-1基因的肿瘤浸润淋巴细胞及其应用 |
| WO2025082418A1 (zh) * | 2023-10-18 | 2025-04-24 | 苏州沙砾生物科技有限公司 | 一种鉴定靶标的方法及其应用 |
| CN117883382B (zh) * | 2023-11-27 | 2025-02-14 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 高效递送疫苗的脂质体载体及脂质体疫苗的制备与用途 |
| WO2025126049A2 (en) * | 2023-12-11 | 2025-06-19 | Crispr Therapeutics Ag | Multiplex gene editing |
| WO2025223340A1 (zh) * | 2024-04-22 | 2025-10-30 | 苏州沙砾生物科技有限公司 | 一种鉴定靶标的方法及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7348139B1 (en) * | 2001-04-13 | 2008-03-25 | The Johns Hopkins University School Of Medicine | SOCS-1 gene methylation in cancer |
| EP1781338A4 (en) * | 2004-07-19 | 2010-02-10 | Baylor College Medicine | MODULATION OF CYTOKIN SIGNALING REGULATORS AND APPLICATIONS FOR IMMUNOTHERAPY |
| US20130331294A1 (en) * | 2007-11-09 | 2013-12-12 | Fox Chase Cancer Center | Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders |
| WO2010098429A1 (ja) * | 2009-02-27 | 2010-09-02 | 国立大学法人大阪大学 | 免疫アジュバント組成物、及びその利用 |
| US20150017136A1 (en) * | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| WO2014066137A1 (en) * | 2012-10-22 | 2014-05-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for enhancing cancer immunotherapy |
| CN105431524B (zh) * | 2013-06-10 | 2020-04-21 | 达娜-法勃肿瘤研究所公司 | 用于降低肿瘤细胞的免疫抑制的方法和组合物 |
| JP2016536021A (ja) * | 2013-11-07 | 2016-11-24 | エディタス・メディシン，インコーポレイテッド | ＣＲＩＳＰＲ関連方法および支配ｇＲＮＡのある組成物 |
| EP3154555A4 (en) * | 2014-06-10 | 2018-02-28 | Monash University | Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer |
| WO2018148378A1 (en) * | 2017-02-08 | 2018-08-16 | Dana-Farber Cancer Institute, Inc. | Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy |
| EP3765608A4 (en) * | 2018-03-15 | 2022-01-12 | KSQ Therapeutics, Inc. | GENE REGULATORY COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY |
| JP2023542348A (ja) * | 2020-09-23 | 2023-10-06 | クリスパー セラピューティクス アクチェンゲゼルシャフト | Ｒｅｇｎａｓｅ－１及び／又はＴＧＦＢＲＩＩを破壊した遺伝子操作されたＴ細胞は機能性及び持続性を改善させた |
-
2020
- 2020-02-04 WO PCT/US2020/016623 patent/WO2020163365A2/en not_active Ceased
- 2020-02-04 AU AU2020217715A patent/AU2020217715A1/en active Pending
- 2020-02-04 US US16/781,732 patent/US20200347386A1/en active Pending
- 2020-02-04 MX MX2021009357A patent/MX2021009357A/es unknown
- 2020-02-04 CA CA3128823A patent/CA3128823A1/en active Pending
- 2020-02-04 BR BR112021015170-2A patent/BR112021015170A2/pt unknown
- 2020-02-04 KR KR1020217028228A patent/KR20210138587A/ko active Pending
- 2020-02-04 SG SG11202108452WA patent/SG11202108452WA/en unknown
- 2020-02-04 EP EP20751889.5A patent/EP3920942A4/en active Pending
- 2020-02-04 JP JP2021545400A patent/JP2022519595A/ja active Pending
- 2020-02-04 CN CN202080012560.2A patent/CN113396216A/zh active Pending
-
2021
- 2021-08-02 IL IL285307A patent/IL285307A/en unknown
-
2024
- 2024-06-19 JP JP2024098698A patent/JP2024111155A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020163365A5 (enExample) | ||
| JP7698828B2 (ja) | Ｒｎａを編集する方法および組成物 | |
| JP2023055884A5 (enExample) | ||
| JP6929791B2 (ja) | エピゲノム編集のための組成物および方法 | |
| Bernstein et al. | TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts | |
| JPWO2019178422A5 (enExample) | ||
| Lawrie | Micro RNA s and lymphomagenesis: a functional review | |
| JPWO2019178421A5 (enExample) | ||
| JP2025061660A (ja) | Ｒｎａ誘導型エンドヌクレアーゼを使用するｄｎａ組み込みのための改善された方法 | |
| KR20230146127A (ko) | 암 면역요법을 위한 crispr-cpf1-관련 방법, 조성물 및 구성성분 | |
| JP2024133347A (ja) | Ｒｎａ誘導型エンドヌクレアーゼを使用したｄｎａ構築物の組み込みプロセスの向上 | |
| JP2022509017A (ja) | 抗ｐｔｋ７免疫細胞癌療法 | |
| JPWO2019178420A5 (enExample) | ||
| JP2021502077A5 (enExample) | ||
| WO2022012531A1 (zh) | 一种经修饰的免疫细胞的制备方法 | |
| AU2021369494A1 (en) | Safe harbor loci | |
| CN117460541A (zh) | 增强用于细胞疗法的分离的细胞治疗功效的方法 | |
| CN108495640A (zh) | 短发夹rna(shrna734)及其用于阳性选择和消除遗传修饰的细胞的用途 | |
| WO2022261115A1 (en) | Peptide nucleic acids for spatiotemporal control of crispr-cas binding | |
| JP2025049296A (ja) | 高度にコンパクトな多入力論理ゲートをコードする核酸ベクターを使用して疾患を処置する方法 | |
| WO2024059821A2 (en) | Car t cell compositions for treatment of cancer | |
| JP2025517469A (ja) | 増殖依存性の遺伝子発現を示す、核酸で改変された生体細胞 | |
| CN111788302A (zh) | 修饰的t细胞及其用途 | |
| KR20230102519A (ko) | 특이적 전달을 위한 핵산 나노구조 복합체 및 그 용도 | |
| JPWO2020193628A5 (enExample) |